Stephen Hoge Buys Shares of Moderna, Inc.

Stephen Hoge, the President of Moderna, Inc. (NasdaqGS: MRNA), made a significant stock purchase on June 15, 2026. Hoge acquired 53,336 shares at an average price of $19.15, totaling approximately $1.02 million. This transaction was not part of a pre-arranged trading plan.

Insider Buying and Selling at Moderna, Inc.

Stephen Hoge's recent purchase adds to his holdings in the company. On the same day, he also sold 53,336 shares at $51.37 as part of a planned transaction. Other notable insider activity includes Shannon Thyme Klinger, Chief Legal Officer, and James Mock, Chief Financial Officer, each buying 11,798 shares on June 5, 2026.

Other Institutional Activity in Moderna, Inc.

FMR LLC increased its stake in Moderna by 17.6 million shares, bringing its total to 45.7 million shares valued at about $2.32 billion. BlackRock, Inc. trimmed its position by nearly 2.9 million shares, now holding 29.6 million shares worth approximately $1.51 billion. Vanguard Capital Management LLC added 22.9 million shares, matching its total holdings in the company. Baillie Gifford & Co reduced its stake by 594,638 shares, ending with 19.9 million shares valued at $1.02 billion. Capital World Investors boosted its holdings by 5.9 million shares, totaling 18.7 million shares worth $949.8 million.

Moderna, Inc. Stock Down 59.9%

Shares of NasdaqGS:MRNA traded near $55.40. Moderna, Inc. has a market cap of $21.98 billion, and a beta of 1.03. Over the past year, the stock has ranged from $22.28 to $59.55. It has a 50-day moving average of $49.73 and a 200-day moving average of $38.83. The company's current ratio is 2.41, with a quick ratio of 2.24 and a debt-to-equity ratio of 17.52.

Recent Earnings

Moderna reported revenue of $2.22 billion, with a modest growth rate of 2.6%. However, the company is not profitable, showing a net margin of -143.6% and a return on equity of -36.6%. The next earnings report is anticipated on July 31, 2026.

Analysts Set New Price Targets

On June 8, 2026, B of A Securities maintained a 'sell' rating for Moderna with a price target of $34. UBS, Goldman Sachs, Evercore ISI Group, and RBC Capital each maintained 'hold' ratings with targets ranging from $38 to $50. The consensus among 20 analysts is a 'hold' rating, with a target mean price of $43.30.

About Moderna, Inc.

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing messenger RNA medicines. It offers a range of vaccines for respiratory, latent, and enteric viruses, as well as oncology therapeutics and rare disease products. The company collaborates with several organizations, including Merck & Co., Inc., Vertex Pharmaceuticals, and The Bill & Melinda Gates Foundation. Moderna was founded in 2010 and is led by CEO Stéphane Bancel.

Bottom Line

Stephen Hoge's recent stock purchase reflects his confidence in Moderna's potential. Investors often track insider transactions for insights into management's perspective. It's important to remember that 13F filings and insider transactions are backward-looking and may not represent current positions.